Data for: Efficacy and long-term survival of advanced lung adenocarcinoma patients with uncommon EGFR mutations treated with 1st generation EGFR-TKIs compared with chemotherapy as first-line therapy

Published: 14 Feb 2019 | Version 1 | DOI: 10.17632/9g58y64x5d.1
Contributor(s):

Description of this data

Supplemental figure. The effect of EGFR-TKIs in patients with uncommon EGFR mutations showed a similar PFS, but OS was lower than in advanced lung adenocarcinoma patients with common EGFR mutations.

Experiment data files

This data is associated with the following publication:

Efficacy and long-term survival of advanced lung adenocarcinoma patients with uncommon EGFR mutations treated with 1st generation EGFR-TKIs compared with chemotherapy as first-line therapy

Published in: Lung Cancer

Latest version

  • Version 1

    2019-02-14

    Published: 2019-02-14

    DOI: 10.17632/9g58y64x5d.1

    Cite this dataset

    Wang, Huijuan (2019), “Data for: Efficacy and long-term survival of advanced lung adenocarcinoma patients with uncommon EGFR mutations treated with 1st generation EGFR-TKIs compared with chemotherapy as first-line therapy”, Mendeley Data, v1 http://dx.doi.org/10.17632/9g58y64x5d.1

Statistics

Views: 178
Downloads: 117

Categories

Fig

Licence

CC BY NC 3.0 Learn more

The files associated with this dataset are licensed under a Attribution-NonCommercial 3.0 Unported licence.

What does this mean?
You are free to adapt, copy or redistribute the material, providing you attribute appropriately and do not use the material for commercial purposes.

Report